It leads to greater inotrophy by increasing the calcium sensitivity as it binds to troponin and this results in a greater positive inotrophic force. Secondly, the drug is able to open ATP sensitive potassium channels in vascular smooth muscle cells, and the vascular dilatory effects of the drug lead to a decreased preload and afterload, putting less work on the heart. This drug is in the process of review by the FDA but has not been approved for use in the United States yet.
The drug improves inotrophy by enhancing calcium sensitivity through troponin binding, leading to a stronger positive inotrophic force. It also activates ATP-sensitive potassium channels in vascular smooth muscle cells, reducing preload and afterload, which decreases heart work. This medication is currently under FDA review but has not been approved for use in the United States.